These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 26680372)

  • 1. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
    OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
    Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY; Kaneku H; Farmer DG
    Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
    Everly MJ
    Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
    Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
    Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients.
    Hirai T; Furusawa M; Omoto K; Ishida H; Tanabe K
    Transplantation; 2014 Aug; 98(4):443-50. PubMed ID: 24717219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.
    Brokhof MM; Sollinger HW; Hager DR; Muth BL; Pirsch JD; Fernandez LA; Bellingham JM; Mezrich JD; Foley DP; D'Alessandro AM; Odorico JS; Mohamed MA; Vidyasagar V; Ellis TM; Kaufman DB; Djamali A
    Transplantation; 2014 Mar; 97(6):612-7. PubMed ID: 24531846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
    Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
    Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
    Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
    Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual literature review of donor-specific HLA antibodies after organ transplantation.
    Kaneku H
    Clin Transpl; 2011; ():311-8. PubMed ID: 22755424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
    Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
    Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.
    Everly MJ
    Clin Transpl; 2011; ():333-6. PubMed ID: 22755427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
    Kimball PM; McDougan FA; King A
    Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.